Physician profile
Thomas E Dunlap
NPI 1932106002
$6,258.33
in general payments reported to CMS, 2019-2025
31 companies · $776 in 2025
The $776 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $570 · 2021: $1,137 · 2022: $868 · 2023: $874 · 2024: $1,128 · 2025: $776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,765 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,764.88 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,301.93 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $631.21 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $603.55 | 2021-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $579.67 | 2019-2024 | Assurity, Cardiomems |
| Edwards Lifesciences Corporation | $470.51 | 2020-2024 | Mitris Resilia Mitral Valve, Sapien 3 Ultra Resilia |
| Esperion Therapeutics, INC. | $412.56 | 2021-2025 | Nexletol |
| Medtronic Vascular, INC. | $333.16 | 2019-2020 | |
| Medtronic, INC. | $271.01 | 2021-2023 | Linq II |
| Astrazeneca Pharmaceuticals LP | $231.77 | 2019-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $211.46 | 2022-2025 | Watchman Flx, Watchman Access System |
| Angiodynamics, INC. | $142.21 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.72 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $108.35 | 2019-2022 | |
| Pfizer INC. | $93.60 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $75.87 | 2020-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $68.16 | 2019-2023 | Xarelto |
| Impulse Dynamics (USA) INC. | $65.88 | 2022-2023 | Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $62.07 | 2021-2023 | Lifevest |
| Braemar Manufacturing, LLC | $60.98 | 2019 | |
| Merck Sharp & Dohme LLC | $55.23 | 2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $45.72 | 2021 | |
| Sanofi-Aventis U.S. LLC | $44.70 | 2019 | |
| Novo Nordisk INC | $43.37 | 2023-2024 | Ozempic, Rybelsus |
| Abiomed | $42.61 | 2022 | |
| Alnylam Pharmaceuticals INC. | $32.13 | 2025 | Onpattro |
| Inspire Medical Systems, INC. | $31.09 | 2025 | Inspire |
| Bardy Diagnostics, INC. | $29.58 | 2021 | |
| United Therapeutics Corporation | $23.81 | 2020 | |
| Amarin Pharma, INC. | $22.08 | 2020 | |
| Philips North America LLC | $21.07 | 2020 | |
| Preventice Services, LLC | $15.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Dunlap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.